Supplementary Materials
The PDF file includes:
- Materials and Methods
- Fig. S1. Structural characterization of CD40L-Tn3 molecule and interactions.
- Fig. S2. Mouse surrogate Tn3 shows potent neutralizing activity in vivo in response to immunization.
- Fig. S3. Study design for phase 1a study to evaluate safety of VIB4920.
- Fig. S4. Phase 1b study design to evaluate VIB4920 in patients with RA.
- Fig. S5. Dose-dependent reduction in DAS28-CRP and RF autoantibodies in RA in response to VIB4920.
- Fig. S6. Impact of VIB4920 on tender/swollen joint counts and CRP in phase 1b study in patients with RA.
- Table S1. Fusion with serum albumin greatly improves half-life of Tn3 molecule.
- Table S2. VIB4920 demonstrates a good safety profile in healthy volunteers.
- Table S3. VIB4920 demonstrates an acceptable safety profile in patients with RA.
- Table S4. DAS28 categories at day 85.
Other Supplementary Material for this manuscript includes the following:
- Data file S1 (Microsoft Excel format). Primary data.